Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $568,748 | $551,478 | $552,131 | – |
| % Growth | 3.1% | -0.1% | – | – |
| Cost of Goods Sold | $254,085 | $249,795 | $235,218 | – |
| Gross Profit | $314,663 | $301,683 | $316,912 | – |
| % Margin | 55.3% | 54.7% | 57.4% | – |
| R&D Expenses | $23,495 | $21,591 | $22,451 | – |
| G&A Expenses | $0 | $0 | $0 | – |
| SG&A Expenses | $210,488 | $236,436 | $203,177 | – |
| Sales & Mktg Exp. | $0 | $0 | $0 | – |
| Other Operating Expenses | $0 | $0 | $0 | – |
| Operating Expenses | $233,983 | $258,028 | $225,627 | – |
| Operating Income | $80,680 | $43,656 | $91,285 | – |
| % Margin | 14.2% | 7.9% | 16.5% | – |
| Other Income/Exp. Net | $23,919 | $6,579 | $11,868 | – |
| Pre-Tax Income | $104,598 | $50,235 | $103,153 | – |
| Tax Expense | $20,963 | $7,973 | $28,092 | – |
| Net Income | $81,665 | $41,329 | $75,589 | – |
| % Margin | 14.4% | 7.5% | 13.7% | – |
| EPS | 0.36 | 0.18 | 0.33 | – |
| % Growth | 100% | -45.5% | – | – |
| EPS Diluted | 0.36 | 0.18 | 0.33 | – |
| Weighted Avg Shares Out | 225,964 | 226,474 | 228,139 | – |
| Weighted Avg Shares Out Dil | 228,928 | 228,860 | 228,793 | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,645 | $1,607 | $1,743 | – |
| Interest Expense | $2,193 | $2,566 | $2,773 | – |
| Depreciation & Amortization | $28,346 | $30,964 | $25,777 | – |
| EBITDA | $135,137 | $83,765 | $131,703 | – |
| % Margin | 23.8% | 15.2% | 23.9% | – |